Literature DB >> 20686466

Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.

Millie D Long, Douglas A Drossman.   

Abstract

Many patients with inflammatory bowel disease (IBD) in clinical remission continue to have symptoms of pain and diarrhea despite minimal or no ongoing inflammation. These patients may be considered to have an overlap of IBD and irritable bowel syndrome (IBD-IBS). In this month's Journal, a proposal is made that continued symptoms in patients with elevated calprotectin, a marker of inflammation, is related to IBD. We propose an alternate biopsychosocial model whereby mutual effects of peripheral and central factors influence symptom generation in both IBD and IBS. Understanding this model has important implications for treatment of patients with IBD-IBS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686466     DOI: 10.1038/ajg.2010.162

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  34 in total

Review 1.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

2.  Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Michael D Kappelman; Christopher F Martin; Joshua R Korzenik; Seth D Crockett
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

3.  Narcotic use for inflammatory bowel disease and risk factors during hospitalization.

Authors:  Millie D Long; Edward L Barnes; Hans H Herfarth; Douglas A Drossman
Journal:  Inflamm Bowel Dis       Date:  2011-07-07       Impact factor: 5.325

4.  Inhibition of Cav 3.2 calcium channels: A new target for colonic hypersensitivity associated with low-grade inflammation.

Authors:  Elodie Picard; Frederic Antonio Carvalho; Francina Agosti; Emmanuel Bourinet; Denis Ardid; Alain Eschalier; Laurence Daulhac; Christophe Mallet
Journal:  Br J Pharmacol       Date:  2019-03-11       Impact factor: 8.739

5.  Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease.

Authors:  Heba N Iskandar; Benjamin Cassell; Navya Kanuri; C Prakash Gyawali; Alexandra Gutierrez; Themistocles Dassopoulos; Matthew A Ciorba; Gregory S Sayuk
Journal:  J Clin Gastroenterol       Date:  2014 May-Jun       Impact factor: 3.062

Review 6.  Stress and visceral pain: from animal models to clinical therapies.

Authors:  Muriel Larauche; Agata Mulak; Yvette Taché
Journal:  Exp Neurol       Date:  2011-05-06       Impact factor: 5.330

7.  A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers.

Authors:  Tom Nilsen; Kathrin Sunde; Lars-Olof Hansson; Aleksandra Mandic Havelka; Anders Larsson
Journal:  J Clin Lab Anal       Date:  2016-09-15       Impact factor: 2.352

8.  Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population.

Authors:  A D Lee; B M Spiegel; R D Hays; G Y Melmed; R Bolus; D Khanna; P P Khanna; L Chang
Journal:  Neurogastroenterol Motil       Date:  2016-12-16       Impact factor: 3.598

9.  Neonatal immune challenge followed by adult immune challenge induces epigenetic-susceptibility to aggravated visceral hypersensitivity.

Authors:  J E Aguirre; J H Winston; S K Sarna
Journal:  Neurogastroenterol Motil       Date:  2017-04-25       Impact factor: 3.598

Review 10.  Refractory inflammatory bowel disease-could it be an irritable bowel?

Authors:  Jie Meng; Anurag Agrawal; Peter J Whorwell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-09-11       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.